Therefore, concurrent targeting of the PI3K and JAK/STAT pathways may represent a new therapeutic strategy to maximize efficacy and reduce toxicity of JAK2 inhibitors that are already employed in patients with MPN. Here, JAK2 is linked to myeloproliferative disorder.